AUTHOR=Carbone M. , Della Penna A. , Mazzarelli C. , De Martin E. , Villard C. , Bergquist A. , Line P. D. , Neuberger J. M. , Al-Shakhshir S. , Trivedi P. J. , Baumann U. , Cristoferi L. , Hov J. , Fischler B. , Hadzic N. H. , Debray D. , D’Antiga L. , Selzner N. , Belli L. S. , Nadalin S. 

TITLE=Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement

JOURNAL=Transplant International

VOLUME=36

YEAR=2023

URL=https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2023.11729

DOI=10.3389/ti.2023.11729

ISSN=1432-2277

ABSTRACT=<p>Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD) and a lead indication for liver transplantation (LT) in the western world. In this article, we present a Consensus Statement on LT practice, developed by a dedicated Guidelines’ Taskforce of the European Society of Organ Transplantation (ESOT). The overarching goal is to provide practical guidance on commonly debated topics, including indications and timing of LT, management of bile duct stenosis in patients on the transplant waiting list, technical aspects of transplantation, immunosuppressive strategies post-transplant, timing and extension of intestinal resection and futility criteria for re-transplantation.</p>